30 research outputs found
A parametric study on compression molding of reference parts with integrated features using carbon composite production waste
Laser Assisted Fibre Placement of Thermoplastic Composites:From the theory behind Disney movies to aircraft
Poster presentation at the 26th Engineering Mechanics Symposium, hosted by the Graduate School on Engineering Mechanics. Prize won for best submission in the poster contes
Experimental characterisation of recycled (glass/tpu woven fabric) flake reinforced thermoplastic composites
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial
Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma.
Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We
aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.
Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries.
Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the
minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and
had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were
randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical
apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to
100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a
maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h
for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to
allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients
who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable.
This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.
Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid
(5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated
treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the
tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18).
Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and
placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein
thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of
5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).
Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our
results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a
randomised trial
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
Compression molding of chopped woven thermoplastic composite flakes
Continuous fiber reinforced composites with high-performance thermoplastic polymer matrices have an enormous potential in terms of performance, production rate, cost efficiency and recyclability. The use of this relatively new class of materials by the aerospace and automotive industry has been growing steadily during the last decade. However, the use of continuous reinforcements limit the complexity of the shape of the end products, as defects such as wrinkles can form during processing. Moreover, a significant amount of process waste is generated, which lowers the efficiency of the conventional production processes involving a prepreg cutting stage and/or final trimming stages. The overall efficiency of the manufacturing value chain of composites can be improved by adjoining a complementary manufacturing process that utilizes the process waste incurred in the primary process. The discontinuous form of reinforcements in the reclaimed material will provide a means to manufacture complex 3D geometries with near-net edges and at the same time use the raw material efficiently. However, the discontinuities in the reinforcing phase lead to a reduced mechanical performance compared to continuous reinforcements. Suitable applications include semi-structural parts and non-load bearing structures. This thesis focuses on the processing of planar discontinuous reinforcements and the associated mechanical performance. Chopped thermoplastic semi-preg with a woven fabric reinforcement, referred to as flakes, is considered as a standalone molding compound in this study. A compression molding process is chosen to manufacture parts, as it allows for complex geometries while retaining a long fiber length. Although processing of different types of discontinuous reinforcements has been studied in the past, the processing of the specific class of planar reinforcements with a woven architecture and high fiber content has not been explored so far. The principal objective is to develop a strategy for manufacturing woven-flake reinforced parts with good quality and consistent mechanical properties. For achieving this goal, the flow behavior of chopped woven material, process induced jamming of the material and the mechanical properties of molded plates are experimentally investigated and are explained with theoretical models. The work presented in the thesis shows the multidisciplinary nature of the problem, with strong correlations between the material, process and the design of the part leading to the final part performance. Therefore, a processing strategy is proposed which takes into consideration the aforementioned three basic blocks to manufacture consistent parts. Finally, the proposed strategy is validated by manufacturing a full-scale part with typical design features, which successfully demonstrates the processing capabilities of the material and the developed process
Towards Robust Laser Assisted Fibre Placement: Adapting the process to the incoming material properties
Poster presentation at the 25th Engineering Mechanics Symposium, hosted by the Graduate School on Engineering Mechanic